{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T21:14:41Z","timestamp":1717190081221},"reference-count":59,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T00:00:00Z","timestamp":1290470400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mount Sinai J Medicine"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Urothelial carcinoma of the bladder exists as a spectrum of clinical states ranging from non\u2013muscle\u2010invasive to muscle\u2010invasive to advanced\/metastatic disease. Each clinical state is associated with a unique tumor biology, prognosis, and approach to treatment. The field of personalized medicine offers the promise to individualize therapeutic decisions in each clinical state with the goal of preventing or delaying progression to more advanced disease states while optimizing quality of life. This review will discuss bladder cancer as a paradigm for the development of personalized cancer medicine, focusing on recent efforts, current challenges, and future opportunities. <jats:bold><jats:italic>Mt Sinai J Med 74:587\u2013596, 2010.<\/jats:italic><\/jats:bold> \u00a9 <jats:italic>2010 Mount Sinai School of Medicine<\/jats:italic><\/jats:p>","DOI":"10.1002\/msj.20224","type":"journal-article","created":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T10:17:10Z","timestamp":1290593830000},"page":"587-596","source":"Crossref","is-referenced-by-count":7,"title":["Bladder Cancer: Current Management and Opportunities for a Personalized Approach"],"prefix":"10.1002","volume":"77","author":[{"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,23]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2073"},{"key":"e_1_2_8_4_2","unstructured":"IyerG LinO Al\u2010AhmadieH et al.Identification and characterization of FGFR3 mutations in high\u2010grade bladder cancer. ASCO Genitourinary Cancers Symposium2010: Abstract 296."},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1772909"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.03.062"},{"key":"e_1_2_8_7_2","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm DL.","year":"1992","journal-title":"Urol Clin North Am"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)55272-6"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64044-X"},{"key":"e_1_2_8_10_2","unstructured":"KaramJ ShahJ KaderAK et al.Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. ASCO Genitourinary Cancers Symposium2010: Abstract 275."},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.666"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02292-8"},{"key":"e_1_2_8_14_2","article-title":"Updated results of a randomized controlled trial of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle\u2010invasive bladder cancer","volume":"21","author":"Hall RR.","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.101"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3884"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09217.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0109"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2375"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.5744"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70002-5"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.118"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601580"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)48996-8"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_2_8_26_2","article-title":"Randomized phase III study comparing paclitaxel\/ cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC30987\/ Intergroup Study","volume":"25","author":"Bellmunt J","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"15","key":"e_1_2_8_27_2","article-title":"Randomised phase III trial of vinflunine plus best supportive care vs best supportive care alone as 2nd line therapy after a platinum\u2010containing regimen in advanced transitional cell carcinoma of the urothelium","volume":"26","author":"Bellmunt J","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_28_2","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD\u20101839 (Iressa), an epidermal growth factor receptor\u2010selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello F","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08799.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-009-9194-7"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3922"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.03.017"},{"key":"e_1_2_8_33_2","unstructured":"GalskyMD SonpavdeG HellerstedtBA et al.Phase II study of gemcitabine cisplatin and sunitinib in patients with advanced urothelial carcinoma. ASCO Genitourinary Cancers Symposium2010: Abstract 276."},{"issue":"15","key":"e_1_2_8_34_2","article-title":"A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first\u2010line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU\u20100475","volume":"27","author":"Hahn NM","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311903"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/385123b0"},{"issue":"15","key":"e_1_2_8_37_2","article-title":"Randomized trial of p53 targeted adjuvant therapy for patients with organ\u2010confined node\u2010negative urothelial bladder cancer","volume":"27","author":"Stadler WM","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl435"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00366.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1988"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0798"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24337"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9239-3"},{"issue":"15","key":"e_1_2_8_44_2","article-title":"Target\u2010specific, histology\u2010independent, randomized discontinuation study of lapatinib in patients with HER2\u2010amplified solid tumors","volume":"27","author":"Galsky MD","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09101.x"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0096"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1066"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.1050"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1361"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2638"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.152"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20123"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.937"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1853"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.589"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00030-6"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21370"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603118"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-006-9020-9"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6699"}],"container-title":["Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20224","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/msj.20224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:24:44Z","timestamp":1700569484000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/msj.20224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1002\/msj.20224"],"URL":"https:\/\/doi.org\/10.1002\/msj.20224","archive":["Portico"],"relation":{},"ISSN":["0027-2507","1931-7581"],"issn-type":[{"value":"0027-2507","type":"print"},{"value":"1931-7581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}